Total Payments
$5,009
2024 Payments
$168.13
Companies
45
Transactions
257
Medicare Patients
2,424
Medicare Billing
$356,972
Payment Breakdown by Category
Food & Beverage$4,315 (86.1%)
Education$694.42 (13.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,315 | 245 | 86.1% |
| Education | $694.42 | 12 | 13.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $420.77 | 10 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $411.36 | 24 | $0 (2023) |
| Genentech USA, Inc. | $396.04 | 22 | $0 (2022) |
| PFIZER INC. | $365.88 | 24 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $349.37 | 21 | $0 (2024) |
| Amgen Inc. | $344.98 | 9 | $0 (2023) |
| Janssen Biotech, Inc. | $329.05 | 21 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $245.60 | 15 | $0 (2024) |
| Lilly USA, LLC | $195.24 | 8 | $0 (2023) |
| Puma Biotechnology, Inc. | $174.80 | 10 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $168.13 | 5 | Intera Oncology, Inc ($86.36) |
| 2023 | $662.88 | 22 | Incyte Corporation ($99.95) |
| 2022 | $523.78 | 12 | Amgen Inc. ($192.99) |
| 2021 | $71.20 | 3 | PFIZER INC. ($59.28) |
| 2020 | $102.97 | 6 | Puma Biotechnology, Inc. ($38.56) |
| 2019 | $928.50 | 53 | Genentech USA, Inc. ($150.83) |
| 2018 | $1,721 | 104 | Novartis Pharmaceuticals Corporation ($232.56) |
| 2017 | $830.87 | 52 | Janssen Biotech, Inc. ($132.22) |
All Payment Transactions
257 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/03/2024 | Intera Oncology, Inc | INTERA (Device) | Food and Beverage | In-kind items and services | $86.36 | General |
| Category: ONCOLOGY | ||||||
| 03/18/2024 | PFIZER INC. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: Oncology | ||||||
| 02/23/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $21.60 | General |
| Category: Oncology | ||||||
| 01/29/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $17.07 | General |
| Category: Oncology | ||||||
| 01/06/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.58 | General |
| Category: Hematology/Oncology | ||||||
| 11/27/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.76 | General |
| Category: Oncology | ||||||
| 10/30/2023 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Oncology | ||||||
| 09/15/2023 | Seagen Inc. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $20.13 | General |
| Category: Oncology | ||||||
| 09/05/2023 | Lilly USA, LLC | — | Education | In-kind items and services | $90.21 | General |
| 09/01/2023 | Amgen Inc. | Nplate (Biological), Vectibix, XGEVA | Food and Beverage | In-kind items and services | $15.63 | General |
| Category: Hematology | ||||||
| 08/27/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $23.57 | General |
| Category: Oncology | ||||||
| 08/22/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $25.44 | General |
| Category: Oncology | ||||||
| 08/08/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $22.74 | General |
| Category: Oncology | ||||||
| 07/24/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.94 | General |
| Category: ONCOLOGY | ||||||
| 06/23/2023 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $30.41 | General |
| Category: Oncology | ||||||
| 06/09/2023 | Jazz Pharmaceuticals Inc. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 05/22/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $20.39 | General |
| Category: Oncology | ||||||
| 05/19/2023 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: Oncology | ||||||
| 05/17/2023 | Incyte Corporation | — | Education | Cash or cash equivalent | $99.95 | General |
| 05/10/2023 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: ONCOLOGY | ||||||
| 05/08/2023 | E.R. Squibb & Sons, L.L.C. | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $33.19 | General |
| Category: Hematology | ||||||
| 05/08/2023 | Seagen Inc. | PADCEV (Biological) | Food and Beverage | In-kind items and services | $25.15 | General |
| Category: Oncology | ||||||
| 03/24/2023 | Amgen Inc. | Vectibix (Biological), XGEVA | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Oncology | ||||||
| 03/20/2023 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: ONCOLOGY | ||||||
| 03/17/2023 | Novartis Pharmaceuticals Corporation | TASIGNA (Drug), SCEMBLIX | Food and Beverage | In-kind items and services | $28.22 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 717 | 1,347 | $441,516 | $114,768 |
| 2022 | 13 | 717 | 1,269 | $453,569 | $114,881 |
| 2021 | 11 | 556 | 936 | $300,155 | $79,272 |
| 2020 | 11 | 434 | 632 | $121,382 | $48,050 |
Total Patients
2,424
Total Services
4,184
Medicare Billing
$356,972
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 164 | 380 | $168,340 | $43,986 | 26.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 237 | 549 | $165,798 | $42,897 | 25.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 84 | 116 | $23,780 | $5,862 | 24.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 48 | $17,712 | $4,788 | 27.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 33 | 33 | $18,546 | $4,755 | 25.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 20 | 20 | $10,740 | $2,944 | 27.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 22 | 22 | $8,888 | $2,435 | 27.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 35 | $8,610 | $2,297 | 26.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 31 | 55 | $5,335 | $1,451 | 27.2% |
| G0316 | Prolonged hospital inpatient or observation care evaluation and management service(s) beyond the total time for the primary service (when the primary service has been selected using time on the date of the primary service); each additional 15 minutes by th | Facility | 2023 | 28 | 56 | $5,544 | $1,445 | 26.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 12 | 12 | $4,968 | $1,019 | 20.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 18 | 21 | $3,255 | $889.35 | 27.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 116 | 345 | $161,805 | $41,457 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 203 | 441 | $138,915 | $34,725 | 25.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 77 | 77 | $33,649 | $8,432 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 100 | 143 | $30,745 | $7,213 | 23.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 45 | 45 | $26,685 | $7,068 | 26.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 29 | 42 | $13,692 | $3,560 | 26.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $12,008 | $3,200 | 26.6% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 33 | 33 | $10,659 | $2,755 | 25.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 39 | $8,853 | $2,352 | 26.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 19 | 19 | $8,208 | $2,173 | 26.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 25 | 32 | $3,968 | $1,051 | 26.5% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 14 | 23 | $2,369 | $596.52 | 25.2% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2022 | 11 | 11 | $2,013 | $299.12 | 14.9% |
About Dr. Kimberly Schlesinger, M.D
Dr. Kimberly Schlesinger, M.D is a Hematology & Oncology healthcare provider based in York, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992726335.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kimberly Schlesinger, M.D has received a total of $5,009 in payments from pharmaceutical and medical device companies, with $168.13 received in 2024. These payments were reported across 257 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($4,315).
As a Medicare-enrolled provider, Schlesinger has provided services to 2,424 Medicare beneficiaries, totaling 4,184 services with total Medicare billing of $356,972. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location York, PA
- Active Since 07/21/2006
- Last Updated 11/29/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1992726335
Products in Payments
- OPDIVO (Biological) $204.02
- IBRANCE (Drug) $177.00
- Imbruvica (Drug) $163.94
- DARZALEX (Biological) $151.58
- Nerlynx (Drug) $136.24
- Perjeta (Biological) $121.87
- PEMAZYRE (Drug) $115.82
- ADCETRIS (Biological) $106.39
- Avastin (Biological) $106.36
- JAKAFI (Drug) $105.05
- Pomalyst (Drug) $101.53
- FASLODEX (Drug) $100.80
- MYLOTARG (Biological) $94.96
- INTERA (Device) $86.36
- INJECTAFER (Drug) $69.81
- TASIGNA (Drug) $67.74
- KISQALI (Drug) $67.08
- GILOTRIF (Drug) $64.89
- KEYTRUDA (Biological) $62.76
- Abraxane (Drug) $61.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in York
Dr. Daniel Efiom-Ekaha, Md, MD
Hematology & Oncology — Payments: $346,462
Hematology & Oncology $346,462
Dr. Dan Sotirescu, M.d, M.D
Hematology & Oncology — Payments: $149,275
Hematology & Oncology $149,275
Chanh Huynh, Md, MD
Hematology & Oncology — Payments: $90,450
Hematology & Oncology $90,450
Dr. Joseph Kannarkatt, M.d, M.D
Hematology & Oncology — Payments: $33,488
Hematology & Oncology $33,488
Joyce Huang, Md Phd, MD PHD
Hematology & Oncology — Payments: $28,862
Hematology & Oncology $28,862
Dr. Annie Kannarkatt, M.d, M.D
Hematology & Oncology — Payments: $1,940
Hematology & Oncology $1,940